Form 4: Tenax Therapeutics Updates Stock Option Grants Following Stock Splits

Sentiment:

Stock Option Adjustment Filing


Tenax Therapeutics has adjusted previously reported stock option grants and share counts to reflect stock splits that occurred in 2023 and 2024.

Summary

  • Tenax Therapeutics has filed an update regarding stock options and share counts.
  • The update reflects adjustments due to stock splits that occurred on January 4, 2023, and January 2, 2024.
  • The aggregate number of common stock shares was previously reported as 3,637,871 but has been adjusted to account for the stock splits.
  • Stock options previously reported as covering 6,250 shares at an exercise price of $2.00 per share have been adjusted.
  • Stock options previously reported as covering 5,000 shares at an exercise price of $0.62 per share have also been adjusted.

Sentiment

Score: 7

Explanation: The document is a routine update following stock splits, which is neither positive nor negative, but necessary for transparency. The sentiment is neutral to slightly positive as it shows the company is adhering to standard practices.

Industry Context

Stock splits and subsequent adjustments to share counts and stock options are a common practice for publicly traded companies, especially after significant changes in stock price or capital structure.

Comparison to Industry Standards

  • Adjusting stock options and share counts after stock splits is standard practice across the industry.
  • Companies like Apple and Tesla have also performed stock splits and adjusted their share counts and option grants accordingly.
  • The adjustments made by Tenax Therapeutics are consistent with how other publicly traded companies handle stock splits.

Stakeholder Impact

  • Shareholders will have an updated view of the company's share structure and option grants.
  • Employees holding stock options will have their grants adjusted to reflect the stock splits.

Key Dates

DateDescription
2022-06-10Date of a stock option grant with an expiry of 2031-06-10.
2023-06-09Date of a stock option grant with an expiry of 2032-06-09.
2023-01-04Date of a stock split that required adjustments to share counts and stock options.
2024-01-02Date of a stock split that required adjustments to share counts and stock options.
2024-12-10Date of a stock option grant with an expiry of 2034-12-10.
2024-12-12Date of the filing.
2025-12-10Expiry date of a stock option grant.
2031-06-10Expiry date of a stock option grant.
2032-06-09Expiry date of a stock option grant.
2034-12-10Expiry date of a stock option grant.

Keywords

stock options, stock splits, share count, Tenax Therapeutics, TENX

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.